News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD)'s Head Of Commercial Operations To Step Down


1/7/2014 7:29:47 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Gilead Sciences Inc said on Monday that its head of commercial operations for the past decade, Kevin Young, who oversaw tremendous sales growth at the U.S. biotechnology company, will retire next month. Young, who plans to step down on February 4, has held the top commercial post for the world's leading maker of HIV/AIDS medicines since 2004. During his tenure Gilead's annual sales grew from $1.24 billion in 2004 to about $11 billion in 2013. "Over the past nine years, he has greatly expanded and strengthened our commercial organization, preparing the company to introduce products in new therapeutic areas," Gilead Chief Executive John Martin said in a statement.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters

comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES